TGFB1 and neoplasm: Inhibitors of TGFβ signaling pathways (e.g., fresolimumab, SB431542, SB505124, LY2157299, LY550410, AP12009, Lucanix, GC1008, or CAT-192) may help in blocking the effects of TC-derived TGFβ on EMT, potentially suppressing tumor metastasis and invasion [193,194].